Albertine Donker

Chapter 1 44 journal of medicine. 1994;330(10):675-679. 134. Campagna DR, de Bie CI, Schmitz-Abe K, et al. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations. American journal of hematology. 2014;89(3):315-319. 135. AivadoM, GattermannN, RongA, et al. X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns. Blood cells, molecules & diseases. 2006;37(1):40-45. 136. Cazzola M, May A, Bergamaschi G, Cerani P, Rosti V, Bishop DF. Familial- skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. Blood. 2000;96(13):4363-4365. 137. Cortesao E, Vidan J, Pereira J, Goncalves P, Ribeiro ML, Tamagnini G. Onset of X-linked sideroblastic anemia in the fourth decade. Haematologica. 2004;89(10):1261-1263. 138. Sankaran VG, Ulirsch JC, Tchaikovskii V, et al. X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation. The Journal of clinical investigation. 2015;125(4):1665-1669. 139. May A, Bishop DF. The molecular biology and pyridoxine responsiveness of X-linked sideroblastic anaemia. Haematologica. 1998;83(1):56-70. 140. Cotter PD, May A, Li L, et al. Four newmutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis. Blood. 1999;93(5):1757-1769. 141. Donker AE, Raymakers RA, Vlasveld LT, et al. Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis. Blood. 2014;123(25):3873-3886; quiz 4005. 142. Donker AE, Schaap Schaap CC, Novotny VM, et al. Iron Refractory Iron Deficiency Anemia (IRIDA): A heterogeneous disease that is not always iron refractory. American journal of hematology. 2016.; 91(12):E482-E490. 143. Nie N, Shi J, Shao Y, et al. A novel tri-allelic mutation of TMPRSS6 in iron-refractory iron deficiency anaemia with response to glucocorticoid. British journal of haematology. 2014;166(2):300-303. 144. Donker AE, Brons PP, Swinkels DW. Microcytic anaemia with low transferrin saturation, increased serum hepcidin and non- synonymous TMPRSS6 variants: not always iron-refractory iron deficiency anaemia. British journal of haematology. 2015;169(1):150-151. 145. Donker AE, Raymakers RA, Nieuwenhuis HK, et al. X-linked sideroblastic anaemia due to ALAS(2) mutations in the Netherlands: a disease in disguise. The Netherlands journal of medicine. 2014;72(4):210-217. 146. Donker AE, Galesloot TE, Laarakkers CM et al. Standardized serum hepcidin values in Dutch children: set point relative to body iron changes during childhood. Pediatric blood and cancer. 2020;67(3):e28038. 147. Heeney MM, Campagna DR, Westerman M, Fleming MD. The clinical and genetic spectrum of TMPRSS6 mutations leading to inappropriate hepcidin expression and iron refractory iron deficiency anemia (IRIDA). Paper presented at: Blood2009. 148. Heeney MM, Guo D, De Falco L, et al. Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency. Blood. 2018;132(4):448-452.